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639T. Cymbron et al. / Meta Gene 2 (2014) 638–645haplotype corresponded to TTCGCC (45%), a “risk” haplotype, formed
exclusively by alleles that were reported to increase cholesterol levels.
Some of the variants detected in the full sequencing of the LDLR gene
fell within the ligand-binding domain of this gene, deﬁned by exons 2
to 6. To add information as to the role of such variants, these exons
were sequenced in the remaining 23 possible FH cases. Two missense
alterations (c.185C N T; c.806G N A) were found in this subset of
possible FH cases. The missense alteration c.185C N T, identiﬁed in one
individual, is novel for the Portuguese population. In silico analysis was
not conclusive for this alteration, whose role will have to be further
investigated. This study represents the ﬁrst approach to the estab-
lishment of the mutational proﬁle of FH in the Azores Islands.
© 2014 Published by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Familial hypercholesterolemia (FH; MIM# 143890) is an autosomal dominantly inherited disorder of
cholesterol metabolism that affects approximately 1 in 500 individuals worldwide, thus corresponding to one of
the most commonmendelian disorders (Goldstein et al., 1995). FH is characterized by an excess of low-density
lipoprotein cholesterol (LDL-c) in circulation, leading to deposits in peripheral tissues (xanthomas), and, more
importantly, in the arterial wall, causing premature and accelerated atherosclerosis and an increased risk of
coronary artery disease (CAD) at a young age (Chater et al., 2006). Defects in at least three different genes
encoding for proteins involved in hepatic clearance of LDL-c from the plasma can cause FH. Mutations in the
apolipoproteina B-100 (APOB) and in the proprotein convertase subtilisin/kexin 9 (PCSK9) genes can produce a
phenotype of FH. The most frequently implicated gene, however, is the one encoding for the low-density
lipoprotein receptor (LDLR). Mutations can occur all over the LDLR gene, but the majority of variants fall within
the ligand-binding domain, which is encoded by exons 2 to 6 (Al-Khateeb et al., 2011). Although the diagnostic
algorithmof FH currently involves the screeningof the LDLR,APOB and PCSK9genes,molecular studies have been
showing that in a high number of clinically deﬁned index-cases no pathogenic mutations can be identiﬁed at
these three loci. In the study of Motazacker et al. (2012), for example, 41% of the index-cases could not be
molecularly diagnosed; this percentagewas around 50% in the study of Bourbon et al. (2008). On the other hand,
the role of some genetic variants described in the previously referred loci (LDLR, APOB and PCSK9), remains to be
established (Raﬁq et al., 2011). Synonymous variants, for example, although previously dismissed as
“non-pathogenic”, are increasingly recognized as being associated with clinically relevant phenotypes. In FH
their potential to modulate splicing efﬁciency through the alteration of exon splicing enhancers has been
demonstrated (Bourbon et al., 2008; Defesche et al., 2008; Zhu et al., 2007). Portugal, in contrast to most of the
other Southern European countries, has a high mortality rate due to CAD, which represents the second cause of
death in the country (WHO, 2011). In the Portuguese Azores Islands the death rate from CAD is two-fold higher
than inmainland Portugal (Eurostat, 2009). A previous study using apparently healthy Azorean subjects showed
a high prevalence of dyslipidemia in this population (Borges, 2012). Because FH is one of the risk factors of CAD,
the molecular characterization of 10 Azorean index-cases with possible FH was performed by analyzing the
LDLR, APOB and PCSK9 loci, using a DNA array (LIPOchip) and subsequently sequencing the full LDLR gene. An
adult possible FH case characterized according to the SimonBroomeHeart Research Trust criteria is an individual
with total cholesterol (TC) over 290 mg/dl and/or LDL cholesterol (LDL-c) over 190 mg/dl, and with family
history of myocardial infarction or high level cholesterol (adapted from the Simon Broome Heart Research Trust
(1991). To further clarify the role of some genetic variants detected in the LDLR gene, we additionally sequenced
exons 2 to 6 and the corresponding exon/intron boundaries in a series of 23 index-cases of possible FH.Subjects and methods
At two regional health centers (Vila Franca and Nordeste), blood samples were collected after informed
consent from 33 unrelated index-cases, 23 women (69.7%) and 10 men (30.3%) born in the Azores and of
640 T. Cymbron et al. / Meta Gene 2 (2014) 638–645Azorean ancestry. The individuals selected fulﬁlled the criteria of “possible FH”, according to the Simon Broome
Heart Research Trust (1991). Secondary causes of hypercholesterolemia, such as diabetes, hypothyroidism and
nephrotic syndrome, were considered exclusion criteria. TC was determined for all subjects in collaborating
laboratories, using standardized protocols. LDL-c concentration was calculated by the Friedewald formula
(Friedewald et al., 1972). DNA was extracted using the salting-out method (Miller et al., 1988). From the 33
individuals collected, 10 (7 women and 3 men) who presented high levels of TC and whose samples
simultaneously fulﬁlled the necessary DNA purity and concentration requirements were selected for
microarray analysis. Genotyping was performed using the LIPOchip® Array version 7 (Progenika, Derio,
Spain) (Stef et al., 2013). This platform includes a microarray for the detection of point mutations and small
insertions/deletions (indels) as well as copy number variations in the LDLR gene. All exons of the LDLR gene
were analyzed; the array included the analysis of 207 point mutations in the gene LDLR, 4 mutations in the
gene APOB and seven in the gene PCSK9 (information provided by Progenica). The chip further detects point
mutations in exon 26 of the APOB gene as well as a few mutations in the PCSK9 gene (Palacios et al., 2012).
Whenever the LIPOchip® Array fails to identify mutations a second step is carried out by sequencing the
promoter, the translated exon sequences, and the exon–intron boundaries of the 18 exons of the LDLR gene
(Palacios et al., 2012). For the remaining23 index-cases, exons 2 to 6,whichdeﬁne the ligand-bindingdomain
of the LDLR gene, were sequenced. Primers were designed to ﬂank the entire coding region and the intron–
exon junctions of each exon. All primer sequences, annealing temperatures, as well as expected PCR products
are available upon request. Sequencing of puriﬁed PCR products was performed using the BigDye Terminator
v3.1 sequencing kit (Applied Biosystems) following themanufacturer's protocols and sequenceswere run in an
ABI 310 sequencer (Applied Biosystems).
Haplotypic analyses for the six synonymous variants associated with cholesterol levels were performed
using the Arlequin3.11 software package (Excofﬁer et al., 2005). Allelic frequencies at population level were
obtained for comparative purposes from dbSNP (NCBI) using the 1000 Genomes as a source.Table 1
Genetic variants obtained after LDLR gene sequencing in a total of 33 possible HF cases, grouped by type of variation and set of individuals
used in this study.
LDLR gene sequencing
18 exons, N = 10 Exons 2 to 6, N = 23
Age (Years) Sex (M|F) TC (mg/dl) LDL-C (mg/dl) Age (Years) Sex (M|F) TC (mg/dl) LDL-C (mg/dl)
54 ± 13 3|7 296 ± 18 194 ± 20 50 ± 11 7|16 293 ± 22 204 ± 23
Variant namea Location SNP IDb Variant name Location SNP ID
Missense variants
c.806G N A; p.Gly269Asp Exon 5 rs143992984 c.185C N T; p.Thr62Met Exon 2 No reference
c.1171G N A;p.Ala391Thr Exon 8 rs11669576 c.806G N A; p.Gly269Asp Exon 5 rs143992984
Synonymous variants
c.81C N T; p.Cys27Cys Exon 2 rs2228671 c.81C N T; p.Cys27Cys Exon 2 rs2228671
c.1060 + 7 T N C Intron 7 rs2738442 c.90C N T; p.Asn30Asn Exon 2 No reference
c.1060 + 10G N C Intron 7 rs12710260
c.1359-30C N T Intron 9 rs1003723
c.1413A N G; p.Arg471Arg Exon 10 rs5930
c.1617C N T; p.Pro539Pro Exon 11 rs5929
c.1706-55A N C Intron 11 rs2738447
c.1706-69G N T Intron 11 rs7259278
c.1725C N T; p.Leu575Leu Exon 12 rs1799898
c.1773C N T; p.Asn591Asn Exon 12 rs688
c.1959 T N C;p.Val653Val Exon 13 rs5925
c.2232A N G; p.Arg744Arg Exon 15 rs5927
c.2389 + 46C N T Intron 16 rs2738460
c.2548-80G N A Intron 18 rs2116897
c.2548-42A N G Intron 18 rs6413504
c.* + 52G N A Intron 18 rs14158
a Ofﬁcial name following rules of human genome variation society (HGVS).
b SNP identiﬁcation in NCBI-SNP database.
641T. Cymbron et al. / Meta Gene 2 (2014) 638–645To infer the putative effects of a missense alteration identiﬁed (c.185C N T; p.Thr62Met) several analyses
were performed. The amino acid conservation index (CI), deﬁned as the percentage of species from theNCBI list
that have thewild-type amino acid in a givenposition,was estimated for position 62 of the LDLR protein. A total
of 39 amino acid reference sequences of different mammal species were used for amino acid CI calculation.
Sequences were aligned using Muscle v3.6 (Edgar, 2004). The pathogenicity of the c.185C N T variant was
further studied using the software packages “Mutation Taster” (Schwarz et al., 2010) and “MutPred” (Li et al.,
2009).Results and discussion
Mutation screening (LDLR, APOB and PCSK9) of 10 index-cases of possible FH
In the 10 unrelated “possible FH” cases analyzed using the LIPOchip® Array, no mutations were detected.
The sequencing of the promoter and the 18 exons of the LDLR gene in these individuals revealed the presence of
eighteen variants, corresponding to two missense alterations and sixteen synonymous variants (Table 1). The
sample analyzed therefore contains a high number of variants when compared with samples used in similar
studies, such as the one by Raﬁq et al. (2011); this latter study, which screened the whole LDLR gene in 17
samples of Pakistani origin, described only two synonymous variants (also detected in the present sample). This
indication of high genetic diversity of theAzores is not all together surprising, since previous research conducted
in the Azorean populations, using different genetic systems, has shown considerable levels of diversity (Montiel
et al., 2005; Santos et al., 2003). In one of the 10 individuals analyzed two missense alterations, both in the
heterozygous state, were detected (Table 1). On what concerns the missense alteration identiﬁed at exon 5
(c.806G N A, rs143992984), in silico analysis of this variant predicts that given the high levels of nucleotide and
amino acid conservation, it should be pathogenic (Etxebarria et al., 2012). However, segregation analysis of this
variant in a Portuguese family failed to prove its association with the FH phenotype (Bourbon et al., 2008).
Furthermore, functional validation indicates that this alteration does not impair lipoprotein-binding capacity,
and therefore should be classiﬁed as non-pathogenic (Etxebarria et al., 2012). The other missense alteration
identiﬁed at exon 8 (c.1171G N A, rs11669576) has been classiﬁed as non-pathogenic (www.ucl.ac.uk/ldlr/
LOVDv.1.1.0) and is rare in the Portuguese mainland population (data not shown).Table 2
Demographic, lipid proﬁle and genetic variants in LDLR gene previously associated with LDL-c levels for each of ten individuals with
possible HF analysed in LipoCHIP array. Data in bold are the alleles which are associated with altered cholesterol levels.
Variants previously associated with LDL-c levels
High levels Low levels
Sample
ID
Age Gender TC LDL-c c.1359-30C N T c.1773C N T c.1959 T N C c.2548-42A N G c.81C N T c.1617C N T
rs1003723 rs688 rs5925 rs6413504 rs2228671 rs5929
1 62 F 293 204 C/T C/C T/T A/A C/T C/C
2 48 F 333 189 T/T T/T C/C G/G C/C C/C
3 52 F 281 208 T/T C/T T/C A/G C/T C/C
4 55 M 298 219 C/C C/C T/T A/A C/C C/T
5 27 M 268 198 T/T T/T C/C G/G C/C C/C
6 54 F 317 170 C/C C/C T/T A/A C/T C/C
7 50 F 299 155 T/T C/T T/C G/G C/C C/C
8 43 F 295 175 T/T T/T C/C G/G C/C C/C
9 75 F 292 214 C/T C/T T/C A/G C/T C/C
10 69 M 280 205 C/C C/C T/T A/G C/C C/C
Minor allele frequency
(MAF)
1000
genomes
28% 28% 33% 36% 6% 12%
Present
study
60% 45% 45% 55% 20% 5%
Ancestral
allele
C C T A T C
Total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c).
642 T. Cymbron et al. / Meta Gene 2 (2014) 638–645Six out of the sixteen synonymous variants identiﬁed in the present study (Table 1), which have
been consistently conﬁrmed in several studies as being associated with alterations in cholesterol levels
(Linsel-Nitschke et al., 2008; Martinelli et al., 2010; Miljkovic et al., 2010), are described in detail in Table 2.
When compared with the normal population, a higher frequency of the risk alleles was observed in the 10
index-cases of possible FH (Table 2). Concerning 2 synonymous variants related to low LDL-c levels the T
variant at c.81C N T, rs2228671 was found in the heterozygous state in 4 subjects (40%). This allele reaches a
frequency of approximately 6% in Europe andappears to have the strongest associationwith LDL-c levels across
multiple European populations, each copy being related to a decrease of LDL-c levels and to a signiﬁcantly
lower risk of coronary artery disease (Linsel-Nitschke et al., 2008). By the other hand, the T allele of the
synonymous variant c.1617C N T, rs5929 is very rare in populations of European ancestry (Miljkovic et al.,
2010). Noteworthy, the T allele is present in one of the 10 index-cases analyzed (10%); this variant displays its
higher percentage inAfrican populations such as the Yoruba inNigeria (12.3%) and theMasai in Kenya (13.5%);
a strong association of this allelewith a protective role concerning LDL-c levels inmulti generational families of
African descent has been described (Miljkovic et al., 2010). The presence of an allele typical of African
populations in the analyzed sample could be justiﬁed by the Azorean population genetic background. In fact,
both historical and genetic data support a sub-Saharan African contribution to the peopling of the Azores
(Matos, 1989; Mendonça, 1996).
In the total of 10 index-cases analyzed seven different haplotypes for the six synonymous variants
associated with cholesterol levels (Table 2) were present (data not shown). The most frequent haplotype is
TTCGCC (45%), which is a “risk” haplotype, being formed exclusively by risk alleles. This haplotype is present
in 3 subjects (2, 5 and 8).Analysis of exons 2 to 6 of the LDLR gene in an additional series of 23 possible FH index-cases
To add information as to the role of the variants detected in the initial 10 index-cases, 23 additional
cases of possible FH were also studied. For these samples, demographic and lipid proﬁle data are presented
in Table 3. The sequencing of exons 2 to 6 of the LDLR gene of these 23 cases allowed the identiﬁcation ofTable 3
Demographic and lipid proﬁle data for each of 23 individuals selected for the analysis of exons 2 to 6 of the LDLR gene.
Sample ID Age Gender TC LDL-c
11 57 F 293 201
12 58 F 329 238
13 26 F 352 266
14 52 F 290 214
15 56 M 266 192
16 71 M 297 186
17 54 M 269 194
18 41 F 280 207
19 60 F 269 194
20 63 F 278 207
21 58 F 305 211
22 34 F 300 209
23 54 M 311 225
24 49 M 300 150
25 44 M 265 191
26 53 M 287 193
27 51 F 322 233
28 46 F 285 193
29 53 F 320 221
30 47 F 265 195
31 56 F 277 195
32 21 F 307 176
33 44 F 280 205
Total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-c) levels are represented as mg/dl. M = male and F = female.
Fig. 1. Shows 4 pedigrees of cases included in our sample, as illustrative of the types of dyslipidemia present in these “possible cases”. These pedigrees show an autosomal dominant pattern of
inheritance, characteristic of FH.
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644 T. Cymbron et al. / Meta Gene 2 (2014) 638–645four variants (Table 1): two of these were missense alterations, both transitions and in a heterozygous
state; the 2 remaining alterations correspond to synonymous variants. The missense alteration c.806G N A,
rs143992984 was already found in the mutation screening of the 10 index-cases of possible FH (Table 1).
Concerning the missense alteration c.185C N T, identiﬁed in one individual, is reported in the British Heart
Foundation database (www.ucl.ac.uk/ldlr/LOVDv.1.1.0) for Caucasians populations, but is novel for the
Portuguese population (data not shown). No functional studies have been performed for this alteration
(Fouchier et al., 2005), whose in silico analysis predicts not to be pathogenic. The amino acid CI estimated for
position 62 of the LDLR protein across the protein reference sequences of the class Mammals that is 89.7%,
suggesting it to be a highly stable position. Because in silico analysis of this variant failed to produce conclusive
results, and since segregation studies were impossible to perform, the association of this variant with the
phenotype remains to be established.
In exon 2 two synonymous variations were also detected (Table 1). The variant c.81C N T, rs2228671 was
detected in 10 individuals, and is frequent in the Portuguese mainland population (data not shown); on the
other hand the c.90C N T variant, identiﬁed in one individual of our sample is also being described for the ﬁrst
time for the Portuguese population (data not shown). Fig. 1 shows 4 pedigrees of cases included in our sample,
as illustrative of the types of dyslipidemia present in these “possible cases”. These pedigrees show an autosomal
dominant pattern of inheritance, characteristic of FH.
Although no pathogenic mutations were found in the studied population, several genetic alterations
were detected, allowing the establishment of a FH variant proﬁle in the Azores. This proﬁle deserves further
investigation, since data derived will promote the early detection of this disease and the minimization of its
impact.
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